Barriers to adoption of biosimilar insulins in Europe: A mixed‐methods study
Authors' conclusion
This study highlights interrelated factors contributing to the limited adoption of biosimilar insulin in Europe. Addressing these barriers through targeted policy interventions may support more informed decision making and facilitate biosimilar insulin adoption in the future.
Study context
- Population
- EMA-approved insulin products and their reimbursement status in nine European countries; physiciansphysicians interviewed
- Participants
- 20 participants
- Outcome
- EMA-approved insulin products and reimbursement; factors influencing prescribing
- Follow-up
- 1996–2022
Methodological detailsquantitative analysis of EMA-approved insulin products and reimbursement status, semi-structured interviews
- Quantitative analysis of EMA-approved insulin products and reimbursement status
- Semi-structured interviews
Main finding
As reported in the abstract
1996–2022
- Insulin products with EMA approval
- 43
- Biosimilars among approvals
- six (14.0%)
- Approvals from Novo Nordisk
- 39.1%
- Approvals from Sanofi
- 32.6%
- Approvals from Eli Lilly
- 23.9%
- Average share of EMA-approved insulin products reimbursed across nine countries
- 56.3%
- Reimbursed share, Netherlands (highest)
- 71.7%
- Reimbursed share, Belgium (lowest)
- 41.3%
- Thematic domains influencing physician prescribing
- six
- Distinct factors
- 14
Original publication
Barriers to adoption of biosimilar insulins in Europe: A mixed‐methods study. Diabetes Obes Metab. Published 1 September 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →